Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

NCT00064974 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00064974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00064974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
February 28, 2007
Enrollment
215 (actual)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes